Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Thiéblemont, Catherine; Howlett, Susannah; Casasnovas, Olivier; Mounier, Nicolas; Perrot, Aurore; Morschhauser, Franck; Fruchart, Christophe; Daguindau, Nicolas; Eygen, Koen Van; Obéric, Lucie; Bouabdallah, Réda; Pica, Gian Matteo; Nicolas‐Virezelier, Emmanuelle; Abraham, Julie; Fitoussi, Olivier; Snauwaert, Sylvia; Eisenmann, Jean‐Claude; Lionne‐Huyghe, Pauline; Bron, Dominique; Tricot, Sabine; Deeren, Dries; Gonzalez, Hugo; Costello, Régis; Dû, Katell Le; Silva, Maria Gomes da; Grosicki, Sebastian; Trotman, Judith; Catalano, John; Caballero, Dolores; Greil, Richard; Cohen, Amos; Gaulard, Philippe; Roulin, Louise; Takeshita, Kenichi; Casadebaig, Marie‐Laure; Tilly, Hervé

doi:10.1111/bjh.16300

Cited by 16 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study population included 2030 baseline PET/CT of FDG-avid lymphomas—HL (n = 777), DLBCL (n = 851) and FL (n = 402)—collected from anonymized multicenter imaging trial datasets of the Lymphoma Study Association (LYSA): 703 for AHL2011 [ 12 ], 573 for GAINED [ 13 ], 277 for RELEVANCE [ 14 ], 217 for REMARC [ 3 ], 125 for FLIP [ 15 ], 61 LNH2007-3B [ 16 ] and 74 for PVAB [ 17 ] ( Table 1 ).…”

Section: Methodsmentioning

confidence: 99%

“…The total metabolic tumor volume (TMTV) has recently been proposed as a tumor burden quantification method in various lymphoma subtypes, especially in Hodgkin lymphoma (HL) [ 1 , 2 ], diffuse large B cell lymphoma (DLBCL) [ 3 ] and follicular lymphoma (FL) [ 4 ]. This evaluation requires whole-body segmentation of the tumor mass on the baseline 18FDG PET/CT imaging.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

et al. 2022

Self Cite

View full text Add to dashboard Cite

The total metabolic tumor volume (TMTV) is a new prognostic factor in lymphomas that could benefit from automation with deep learning convolutional neural networks (CNN). Manual TMTV segmentations of 1218 baseline 18FDG-PET/CT have been used for training. A 3D V-NET model has been trained to generate segmentations with soft dice loss. Ground truth segmentation has been generated using a combination of different thresholds (TMTVprob), applied to the manual region of interest (Otsu, relative 41% and SUV 2.5 and 4 cutoffs). In total, 407 and 405 PET/CT were used for test and validation datasets, respectively. The training was completed in 93 h. In comparison with the TMTVprob, mean dice reached 0.84 in the training set, 0.84 in the validation set and 0.76 in the test set. The median dice scores for each TMTV methodology were 0.77, 0.70 and 0.90 for 41%, 2.5 and 4 cutoff, respectively. Differences in the median TMTV between manual and predicted TMTV were 32, 147 and 5 mL. Spearman’s correlations between manual and predicted TMTV were 0.92, 0.95 and 0.98. This generic deep learning model to compute TMTV in lymphomas can drastically reduce computation time of TMTV.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…A phase III randomized REMARC trial documented that lenalidomide maintenance improved PFS versus placebo in elderly patients with DLBCL responding to first-line R-CHOP. 41,42 Basic resources Not applicable.…”

Section: 7mentioning

confidence: 99%

“…Enhanced resources Lenalidomide maintenance (2B) for patients age 60-80 years 41 as per physician and patient discretion (86% agreement, and one suggestion to avoid, one suggestion to use in partial response [PR], and one suggestion to use in clinical trial).…”

Section: 7mentioning

confidence: 99%

Diagnosis and Management of Diffuse Large B-Cell Lymphoma: Society of Medical Oncology, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline

Iftikhar¹,

Mir

Moosajee

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the commonest non-Hodgkin lymphoma encountered by hematopathologists and oncologists. Management guidelines for DLBCL are developed and published by countries with high income and do not cater for practical challenges faced in resource-constrained settings. This report by a multidisciplinary panel of experts from Pakistan is on behalf of three major national cancer societies: Society of Medical Oncology Pakistan, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology. The aim is to develop a practical and standardized guideline for managing DLBCL in Pakistan, keeping in view local challenges, which are similar across most of the low- and middle-income countries across the globe. Modified Delphi methodology was used to develop consensus guidelines. Guidelines questions were drafted, and meetings were convened by a steering committee to develop initial recommendations on the basis of local challenges and review of the literature. A consensus panel reviewed the initial draft recommendations and rated the guidelines on a five-point Likert scale; recommendations achieving more than 75% consensus were accepted. Resource grouping initially suggested by Breast Health Global Initiative was applied for resource stratification into basic, limited, and enhanced resource settings. The panel generated consensus ratings for 35 questions of interest and concluded that diagnosis and treatment recommendations in resource-constrained settings need to be based on available resources and management expertise.

show abstract

“… 55 While lenalidomide maintenance was associated with an improvement in PFS in elderly patients with DLBCL, the increased toxicity and lack of a documented overall survival benefit have limited the use of this strategy. 56 , 57 …”

Section: Trials Incorporating Molecular Classificationmentioning

confidence: 99%

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm

Crombie

Armand

2020

JCO

View full text Add to dashboard Cite

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Cited by 16 publications

References 31 publications

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

Diagnosis and Management of Diffuse Large B-Cell Lymphoma: Society of Medical Oncology, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm

Contact Info

Product

Resources

About